Small-Molecule Drug Articles & Analysis
-
Atomwise Invited to Present at the 2022 J.P. Morgan Healthcare Conference
Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference. Atomwise Chief Executive Officer and Co-Founder Abraham Heifets, Ph.D. will lead the presentation. The Atomwise presentation ...
-
Protheragen-ING’s AI-Synthesizer Helps to Streamline the Synthesis of Small Molecule DrugsÂ
In an era where technological advancements are constantly reshaping the landscape of the pharmaceutical industry, Protheragen-ING has emerged as a frontrunner with its cutting-edge AI-synthesizer for small molecule drug synthesis. This revolutionary platform is transforming traditional drug formulation processes by employing a unique combination of machine learning algorithms, advanced ...
-
TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB®
Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed’s clinical ...
By TIKOMED AB
-
Virica’s Founder and CEO Dr. Jean-Simon Diallo interviewed by CTV Ottawa Morning
Virica’s Founder and CEO Dr. Jean-Simon Diallo discusses his latest virology research at the Ottawa Hospital Research Institute, which focuses on Covid-19 and is funded by the Ontario Government, with CTV Ottawa Morning. His team is using a biosensor that detects the interaction with the virus and its receptor which will allow them to rapidly test small molecules and drugs for ...
-
CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective
Appropriate drug formulation is a prerequisite for successful drug development. CD Formulation, a highly specialized CRO service provider, recently announced its capability of offering one-stop pharmaceutical formulation solutions that can make drug development faster, easier, and more cost-effective. Drug formulation, or pharmaceutical formulation, is a universal challenge faced by biotech ...
-
Pronalyse Unveils Insightful Metabolite Identification Services of Biopharmaceuticals
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development services. Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its metabolite identification services of biopharmaceuticals for an accurate and efficient analysis of the metabolism for your biological drugs in vivo. The ...
-
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Sep. 15, 2021-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has received clearance from the US FDA regarding the ...
-
Pronalyse Launches Antibody Drug Conjugates (ADCs) Characterization Service for Drug Discovery
Pronalyse, a new division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services for over 10 years. Creative Proteomics Pronalyse recently announced the launch of antibody-drug conjugates (ADCs) characterization service to ensure the safety and effectiveness of ADCs drugs. In recent years, there has been a global upsurge in the research ...
-
Terray Therapeutics Expands Scientific Advisory Board to Advance AI-Driven Small Molecule Drug Discovery
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointment of Fiona Black, PhD to its Scientific Advisory Board, adding valuable expertise in interdisciplinary technology development of both market-leading, end-to-end product solutions and operationally efficient and scalable manufacturing processes. “We are thrilled to ...
-
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces completion of the Phase I clinical trial for ALS-4 (a first in-class anti-virulence based small molecule drug targeting infections caused by ...
-
CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly ...
-
DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development
BOSTON--(BUSINESS WIRE)-- DermBiont, Inc., a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm, which is developing a topical inhibitor of melanin production as a ...
-
Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative ...
By Iktos
-
Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it has fifteen research collaborations underway with leading global universities to explore broad-spectrum therapies for COVID-19 and other coronaviruses. Coronaviruses are RNA viruses and include the causative SARS-CoV-2 strain of the current COVID-19 global pandemic as well as MERS ...
-
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D. as General Counsel and Corporate Secretary. Lori Kunkel, M.D. and Ron Dror, Ph.D. have also joined ...
-
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
January 20, 2022 at 8:00 AM EST NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 20, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug ...
-
Terray Therapeutics Launches with $60M to Deliver Premium Chemical Data at Unrivaled Scale, Unlocking the Potential of AI-Driven Small Molecule Drug Discovery
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the closing of a $60 million Series A financing to advance its novel tNova platform and deliver therapies to patients faster than ever before. The financing was led by Madrona Venture Group with participation from a broad syndicate of new and existing investors, including Two Sigma ...
-
Axial Therapeutics Announces Participation of its CEO, A. Stewart Campbell, in Longwood Healthcare Leaders Spring MIT Webconference
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel titled “Placing Patients At The Center” at the Longwood Healthcare Leaders Spring MIT webconference ...
-
Cancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer
Cancer Targeted Technology (CTT) receives milestone payment for development of diagnostic PET imaging agent for prostate cancer. Seattle, Washington, June 2021. Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical ...
-
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 18, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum’s SACT-1 repurposed drug for the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you